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Transcriptional Regulation and Characterization
of the Promoter Region of the Human ABCC6
Gene
Qiujie Jiang1,3, Yasushi Matsuzaki1,3, Kehua Li1 and Jouni Uitto1,2
ABCC6, a member of the adenosine 50-triphosphate-binding cassette family of genes, encodes multidrug
resistance-associated protein 6, a putative transmembrane transporter expressed primarily in the liver and to a
significantly lower extent in other tissues. Mutations in ABCC6 result in pseudoxanthoma elasticum, a multi-
system heritable connective tissue disorder with variable phenotypic expression. To examine the transcriptional
regulation and tissue-specific expression of this gene, we cloned 2.6 kb of human ABCC6 promoter and
developed a series of 50-deletion constructs linked to luciferase reporter gene. Transient transfections in a
number of cultured cell lines of diverse origin identified a specific NF-kB-like sequence (235/226), which
conferred high level of expression in HepG2 hepatoma cells, inferring liver specificity. The functionality of the
promoter fragments was confirmed in vivo by tail vein injection followed by luciferase reporter assay. Testing of
selected cytokines revealed that transforming growth factor (TGF)-b upregulated, while tumor necrosis factor
(TNF)-a and interferon (IFN)-g downregulated the promoter activity in HepG2 cells. The responsiveness to TGF-b
was shown to reside primarily within an Sp1/Sp3 cognate-binding site at 58 to 49. The expression of the
ABCC6 promoter was also shown to be markedly enhanced by Sp1 protein, as demonstrated by cotransfection
of ABCC6 promoter–luciferase constructs and an Sp1 expression vector in Drosophila SL2 cells, which are
devoid of endogenous Sp1. Furthermore, four additional transcription factors, with their cognate-binding
sequences present in DNA, were shown to bind the 2.6-kb promoter fragment by protein/DNA array.
Collectively, the results indicate that human ABCC6 displays tissue-specific gene expression, which can be
modulated by proinflammatory cytokines. These findings may have implications for phenotypic expression of
heritable and acquired diseases involving abnormality in the ABCC6 gene.
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INTRODUCTION
ABCC6 (GenBank nos. U91318 and AF076622) encodes
MRP6, a member of the multidrug resistance-associated
protein (MRP) family (Borst et al., 1999). The interest in
ABCC6/MRP6 has been recently heightened by demonstra-
tion of mutations in this gene/protein system in families with
pseudoxanthoma elasticum (PXE), a multi-system disorder
affecting the elastic structures in the skin, the eyes, and the
cardiovascular system (Le Saux et al., 2001; Ringpfeil et al.,
2001a; Uitto et al., 2001). The clinical manifestations
include loose and sagging skin, development of angioid
streaks in the eyes, which can lead to loss of visual
acuity, and development of early cardiovascular disease
(Ringpfeil et al., 2001a; Uitto et al., 2001). As the primary site
of ABCC6 gene expression is the liver, it has been suggested
that PXE is primarily a metabolic disorder due to altered
function of MRP6 as a transmembrane transporter (Uitto
et al., 2001).
The ABCC6 gene comprises 31 exons spanningB73 kb of
genomic DNA on the short arm of chromosome 16, locus
16p13.1. The transcribed messenger ribonucleic acid is
B6 kb, with a coding sequence of 4.5 kb, leading to
translation of a polypeptide with 1503 amino acids. The
function of MRP6 is currently unknown; however, it has been
proposed to be a transmembrane transporter, as sequence
analysis predicts three membrane-spanning domains 1–3 with
five, six, and six transmembrane segments, respectively.
There are two nucleotide-binding folds 1 and 2 (Uitto et al.,
2001), and these domains contain conserved Walker A and B
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motifs critical for the adenosine 50-triphosphate-binding
function, while a conserved C motif, located between the A
and B sequences, is critical for the function of the protein as a
putative transmembrane transporter (Borst et al., 1999).
A surprising finding in the context of the widespread
clinical multi-system involvement in PXE was the observation
that MRP6 is expressed predominantly in the liver (Belinsky
and Kruh, 1999; Kool et al., 1999). The biological function of
MRP6 in the liver is currently unknown; however, MRP1, the
prototype protein within the MRP family, functions as an
efflux pump for amphipathic anionic conjugates (Borst et al.,
1999). Similarly, MRP6 has been recently shown to transport
small-molecular-weight glutathione S-conjugates across the
plasma membranes in vitro, but the physiological signifi-
cance of the substrates being used, including leukotriene C4
and ethylmaleimide S-glutathione, is currently unclear
(Belinsky et al., 2002; Ilia´s et al., 2002).
All mutations in the ABCC6 gene disclosed in families
with PXE thus far are recessive, and most of them are
premature termination codon-causing mutations, that is,
either nonsense mutations, small insertions or deletions
resulting in frameshift, or large deletions (Le Saux et al.,
2001; Ringpfeil et al., 2001a, b; Uitto et al., 2001; Miksch
et al., 2005). Also, a number of missense mutations affecting
critical conserved amino acids within the nucleotide-binding
folds have been disclosed as resulting in functional null
alleles. Thus, most of the cases with classic PXE result from
recessive null mutations in the ABCC6 gene. However, in a
number of patients with PXE, sequencing of the entire coding
region and splice junctions failed to disclose pathogenetic
mutations, raising the possibility that mutations in the
regulatory regions of the ABCC6 gene may underlie some
cases. Furthermore, it has been suggested that some, but not
all, heterozygous carriers of the mutations may show signs
suggestive of PXE (Bacchelli et al., 1999; Sherer et al., 2001).
The latter observations raise the issue of pathological
consequences of subtle modulation of the ABCC6 gene
expression.
Little is known about the transcriptional regulation of the
human ABCC6 gene. A recent study (Ara´nyi et al., 2005) has
identified a methylation-dependent activator sequence in the
50 regulatory region of ABCC6, but nothing beyond that has
been reported. In the present study, we have provided a
comprehensive examination of the transcriptional regulation
and tissue-specific expression of the human ABCC6 gene.
RESULTS
High level of expression of the ABCC6 gene in hepatoma cells
HepG2, a human hepatoma cell line, is expected to express
ABCC6, since human liver shows a relatively high level of
expression of this gene (Belinsky and Kruh, 1999; Kool et al.,
1999). We first performed reverse transcriptase-PCR with
RNA isolated from HepG2 cells, as well as from a number of
other cultured cells of mesenchymal or epithelial origin,
including dermal fibroblasts, HaCaT (a transformed epider-
mal cell line), human embryonic kidney (HEK)293 (a kidney
embryonic cell line), HT1080 (a fibrosarcoma cell line), and
WISH (an amnionic epithelial cell line) cells. Utilization of
primers corresponding to exons 1–6 resulted in a strong band
of the expected size (B650 base pairs (bp)) in HepG2 cells,
and a much weaker band of the same size was noted in the
other cell lines tested (Figure 1a).
Identification of a putative liver-specific cis-element in the
ABCC6 promoter
To search for regulatory cis-elements that might be critical for
expression of the ABCC6 gene in HepG2 cells, we developed
a series of 50 deletion constructs consisting of ABCC6
promoter linked to luciferase reporter gene. The largest
construct had its 50 end at –2631 (p-2631 construct) upstream
from the transcription initiation site (þ 1; Figure 1b). The
transcription initiation site was determined by 50-rapid
amplification of cDNA ends (50-RACE), which revealed that
the transcription site (þ1) resides 30 nucleotides upstream
from the A in the ATG translation initiation codon of the
gene. Transfection of the 50 deletion constructs into HepG2
cells in culture revealed robust expression with the construct
p-2631 as well as with constructs containing deletions down
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Figure 1. Expression of the human ABCC6 gene in cells of various tissue
origins and 50 deletion analysis of the promoter in HepG2 cells. (a) Reverse
transcriptase-PCR was performed using total RNA isolated from cultured
HepG2, dermal fibroblast, HaCaT, HEK293, HT1080, and WISH cells using
primer pairs specific for the human ABCC6 and GAPDH sequences, as
described under Materials and Methods. (b) The ABCC6 promoter fragments
correspond to regions with the 50 ends as indicated in the figure and 30 ends
fixed at þ30 were fused to the luciferase (Luc) reporter gene in pGL3 vector.
Each construct (0.8 mg) was cotransfected with 0.2 mg of pRSV-b-galactosidase
plasmid into HepG2 cells using FuGENE6 reagent (Roche), and 48 hours later
cells were lysed and assayed for luciferase and b-galactosidase activities.
Luciferase activity was divided by b-galactosidase activity to correct for
transfection efficiency, and the results were expressed as relative luciferase
activity. The data are presented as the mean7SD of three independent
experiments each performed in triplicate. The activity of the p-2631 promoter
construct was set arbitrarily as 100.
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to 249 (Figure 1b). However, further deletion of the 50
sequences to 175 resulted in about 80% reduction of the
luciferase activity, and further reduction was noted with
p-109 and p-55 constructs. These observations suggest that
the segment between 249 and 176 contains elements that
confer high level of expression of the ABCC6 gene in HepG2
cells.
To examine whether the sequence 249/176 is a
specific requirement for high level of expression in HepG2
cells, we compared the activity of three constructs (p-2631,
p-249, and p-175) in HepG2 cells with that in HEK293 and
fibrosarcoma cells (HT1080), which expressed ABCC6 at a
very low level (see Figure 1a). Transfection experiments
confirmed that deletion of the 249/176 sequence from the
promoter significantly (480%) reduced the activity in
HepG2 cells, while no statistically significant difference
was noted in the two other cell lines tested with the
constructs p-249 and p-175 (Figure 2). It should be noted
that the basal promoter activity with the p-2631 construct
was about 50 times higher in HepG2 cells than in HEK293
and HT1080 cells, the relative luciferase activity being
43.671.5 106 vs 0.970.06106 and 1.070.05106 in
HepG2, HEK293, and HT1080 cells, respectively (mean7
standard deviation (SD)), after correction of the transfection
efficiency. Thus, the nucleotide segment 249/176 of the
ABCC6 confers high level of expression in the hepatoma
HepG2 cells.
Examination of the nucleotide sequence within the 249/
176 segment revealed the presence of an NF-kB-like
sequence, which differs from the consensus NF-kB-binding
site by substitution of T by C in the sixth position of the 10-bp
consensus sequence (GGGAMTNYCC; M¼A or C; N¼ any
nucleotide; Y¼C or T) (see Figure 3). No homology with
previously published liver-specific cis-elements was noted
within this segment (Hayashi et al., 1999).
To examine for the presence of transacting factors that
might bind to the NF-kB-like sequence, an 18-bp probe,
239/222, was synthesized and used in electrophoretic
mobility shift assay (EMSA) with nuclear proteins isolated
from HepG2 cells. In addition to nonspecific bands, a
radiolabeled DNA/protein complex was noted in electro-
phoresis (Figure 3). Addition of unlabeled probe 239/222
as a competitor abolished this binding in 100-fold excess,
while the nonspecific complexes were not affected. How-
ever, addition of a 22-bp unlabeled oligonucleotide contain-
ing the consensus NF-kB-binding site, in 100-fold excess,
failed to significantly reduce the specific DNA/protein
complex and did not affect the nonspecific binding (Figure 3).
Nevertheless, slight reduction in the intensity of the specific
complex was noted with 350-fold excess of the NF-kB oligo-
mer (not shown). To examine the sequence requirements
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Figure 2. Liver-specific expression of the ABCC6 promoter construct
depends on 249/176 segment. Three truncated promoter constructs
(p-2631, p-249, and p-175) were cotransfected with pRSV-b-galactosidase
plasmid into HepG2, HEK293, and HT1080 cells, as described in the legend
to Figure 1. At 48 hours after transfection, cells were lysed and assayed for
luciferase and b-galactosidase activities, and the results were expressed as
relative luciferase activity. The data are presented as the mean7SD of three
independent experiments, each performed in triplicate. The activity of p-2631
promoter construct was set arbitrarily as 100 for each cell type.
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Figure 3. Binding of HepG2 nuclear proteins to the 239/222 sequence
of the human ABCC6 promoter. (a) Sequences for the WT sense strand of
239/222 oligonucleotide (WT), and the mutant 239/222 oligonucleo-
tides (M1, M2, and M3), with nucleotide substitutions within the NF-kB-like
sequence as delineated by a horizontal bar, are shown. (b) WT239/222
oligonucleotide was labeled with [g-32P]dATP and used as a probe in EMSA
with nuclear extracts (NE) prepared from HepG2 cells. Competition
experiments were performed with 100-fold excess of the unlabeled WT and
mutated (M1-M3), as well as consensus NF-kB-binding, oligonucleotides.
Specific complexes are indicated by an arrowhead and nonspecific (NS)
complexes by arrows. The widened bar at the 50-end of the p-249 promoter
construct indicates the presence of the 249/176 segment.
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for nuclear protein binding within the NF-kB-like sequence in
further detail, three mutant oligomers (M1–M3) were synthe-
sized, which harbored 3-bp substitutions affecting different
parts of the wild-type (WT) sequence (Figure 3). Using these
oligomers as competitors in 100-fold excess revealed that M1
and M2 probes were able to compete for the protein binding
to the same extent as the WT probe (Figure 3b). However,
mutations in probe M3 abolished its ability to compete for
protein binding. Collectively, these findings suggest that
the NF-kB-like sequence provides high level of expression
in liver cells to the ABCC6 promoter. It should be noted
that two putative CCAAT/enhancer-binding protein
cognate sites (Hayashi et al., 1999) were identified at
positions 375 to 366 and 336 to 330. However,
elimination of these sequences (compare constructs p-404,
p-337, and p-249) did not alter the ABCC6 promoter activity
(Figure 1b).
The function of promoter in vivo
To further study the liver-specific characteristics of the human
ABCC6 promoter, we examined the activities of the full-
length (p-2631) and the shorter (p-249) promoter–luciferase
constructs in vivo, utilizing a rapid tail vein injection
technique (Zhang et al., 1999) (Figure 4). An efficient gene
transfer can be achieved in mouse liver by a rapid tail vein
injection of a large volume of plasmid DNA solution
(hydrodynamics-based transfection). The gene transfer effi-
ciency was confirmed by b-galactosidase staining of liver
after transfer of pCMV-LacZ construct into liver with this
technique (Figure 4b). Injections of 100mg ABCC6 promoter–
luciferase construct DNA in 2 ml Ringer’s solution were
performed on sets of three mice per construct. The results
shown in Figure 4a indicate that both promoters are
functional in vivo, and demonstrate significantly elevated
activity compared to the controls injected with 2 ml of
Ringer’s solution alone. However, the full-length promoter
construct (p-2631) yielded significantly higher luciferase
expression and was about 13.6-fold higher than the expres-
sion of the p-249 construct. In vitro, the ratio of expression of
these two constructs wasB0.7. This may reflect the fact that
gene regulation in vivo is a more complex process than in
isolated cells in culture, and more regulatory elements/factors
are probably involved in the expression of ABCC6 in vivo.
Search for binding proteins on the promoter
For a systematic search of the transcription factors that bind to
the ABCC6 transcriptional regulatory region, we used the
p-2631 construct consisting of ABCC6 promoter linked to
luciferase reporter gene to isolate a 2661-bp DNA fragment
spanning nucleotide 2631 to þ 30. This fragment was used
to isolate nuclear proteins which bind to this region of
promoter, and the identities of the transcription factors were
determined by a protein/DNA array-based procedure, as
described in Materials and Methods. The results, shown in
Figure 5, identified a total of 18 transcription factors in the
pulled-down samples. However, among them, only four
factors were found to have the corresponding consensus-
binding sequences within this region of DNA, based on
computer searches, viz., activator protein-2, USF-1, NF-kB,
and epidermal growth receptor (Figure 9).
Cytokine modulation of ABCC6 gene expression and the role
of Sp1/Sp3 in transforming growth factor-b responsiveness
Although there is no evidence that PXE involves tissue
inflammation, PXE-like cutaneous findings have been en-
countered in a number of metabolic, both acquired and
heritable, disorders, some of which involve immunologic and
inflammatory aberrations (Ringpfeil and Uitto, 2005). Since
inflammatory cytokines play a role in a number of
pathological conditions by regulating the expression of genes
at the transcriptional level, we examined the prototypic pro-
inflammatory cytokines, transforming growth factor (TGF)-b,
tumor necrosis factor (TNF)-a, and interferon (IFN-g), for their
effects on the ABCC6 promoter activity in HepG2 cells
transiently transfected with the p-2631 promoter–reporter
gene construct. The results indicated that addition of TGF-b
(0.1–10 ng/ml) increased the promoter activity in a dose-
dependent manner up to about 2.5-fold (Figure 6a). At the
same time, addition of TNF-a (0.1–10 ng/ml) or IFN-g
(10–1,000 U/ml) suppressed the promoter activity (Figure
6a). Further analysis utilizing the 50-deletion constructs
revealed that the constructs with their 50-end either at 337
or at 175 similarly responded to TGF-b (10 ng/ml),
depicting over two-fold increase. Careful search for sequence
homology for known TGF-b response elements, including the
SMAD-binding site (Shi et al., 1998; Zawel et al., 1998),
revealed the presence of a CAGA box-like sequence,
CAGACAGA, superimposed on the transcription initiation
site (3 to þ 7) (Figure 7). Furthermore, at the position 58
to 49 upstream from the transcription initiation site, there
was a consensus Sp1-binding site (Figure 7). To examine the
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Figure 4. Demonstration that the human ABCC6 promoter constructs are
functional in vivo. The promoter–reporter gene constructs were infused into
the tail vein of 3.5-month-old mice using a hydrodynamics-based transfection
method (Zhang et al., 1999). After 24 hours, the mice were euthanized and
examined for the expression of the reporter gene. (a) In all, 100 mg of the
promoter construct, either p-249 or p-2631, linked to a luciferase reporter
gene was injected into the tail vein in 2 ml of Ringer’s solution. The relative
luciferase activity was determined and normalized to mg of liver protein. The
values are mean7standard error of the mean (n¼ 3; each assay performed in
triplicate). *Po0.01, Student’s t-test, as compared to controls injected with
2 ml of Ringer’s solution only. (b) pCMV-lacZ promoter–reporter gene
construct (100mg) was injected to the tail vein of mice as described in (a). The
efficiency of gene delivery to the liver was confirmed by b-galactosidase
staining at 24 hours after injection. As shown, most of the injected DNA was
expressed in the liver, while a low level of expression was noted in other
organs examined.
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role of these two cis-elements in TGF-b responsiveness,
discrete 2- or 4-bp mutations were introduced into these
sequences within the promoter–reporter gene construct
p-337, and the WT and mutated promoters were transfected
to HepG2 cells, followed by incubation with or without
TGF-b (10 ng/ml) (Figure 7). In accordance with the findings
reported above, the WT p-337 promoter construct responded
to TGF-b with about 2.2-fold enhancement of luciferase
activity. Introduction of 2-bp mutations in the CAGA box-like
sequence somewhat reduced, but did not entirely abolish, the
TGF-b responsiveness (Figure 7). However, introduction of
mutations to the putative Sp1-binding site entirely abolished
the upregulation of the promoter activity by TGF-b. These
observations suggest that the consensus Sp1-binding site
plays the primary role in TGF-b response within the ABCC6
promoter.
To examine the role of the Sp1 cognate sequence in
further detail, EMSA was performed with a radiolabeled
probe extending from 62 to 45 (Figure 8a). Incubation of
HepG2 nuclear extracts with the radiolabeled probe revealed
a double band as well as a faster moving band, which were
shown to be specific DNA/protein complexes (Figure 8b, left
arrows). Supershift with antibodies recognizing Sp1 protein
epitopes resulted in disappearance of one of these bands,
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Figure 5. Identification of transcription factors binding to human ABCC6 promoter region by a protein/DNA array. (a) Hybridization signals of the
transcription factors bound to the 2661-bp promoter fragment identified in nuclear extracts of HepG2 cells. The TransSignal protein/DNA filter contains
54 transcription factors, each tested in duplicate (adjacent horizontal dots) and in two different concentrations (adjacent vertical dots, 1:10 dilution). (b) The
transcription factors identified by the protein/DNA array as binding to ABCC6 promoter region are indicated on white background. No signal was noted for those
factors shown on the shadowed background.
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while two different bands disappeared with the Sp3
antibodies with concomitant formation of supershift com-
plexes (Figure 8b). The same three bands were dissolved by
the addition of 50-fold excess of unlabeled 62/45
oligomer (WT) or addition of an oligomer containing the
Sp1 consensus-binding site (Figure 8b). Interestingly, addition
of the Mut162/45 probe (M1) containing a 2-bp mutation
in Sp1-binding sequence partially competed for the WT
62/45 probe binding to the nuclear proteins. However,
introduction of a 4-bp substitution in the Sp1 sequence
(Mut262/45 (M2) probe) abolished the ability to compete
for the WT probe to bind to Sp1/Sp3 proteins. Collectively,
these observations attest to the role of Sp1/Sp3 transacting
factors in regulation of ABCC6 gene expression and its
responsiveness to TGF-b.
Activation of the ABCC6 promoter in Drosophila SL2 cells
by the human Sp1 transcription factor
As Sp1 is expressed in virtually all mammalian cells, we
utilized Drosophila SL2 cells, an established in vitro model
lacking endogenous SP-1 activity, to determine whether the
transcription factor specifically activates the ABCC6 promo-
ter. This was done by transfecting ABCC6 promoter
constructs p-337 and p-249 to SL2 cells. Very low level of
expression was noted when these reporter gene constructs
were expressed together with a control pPAC (-Sp1) vector
(Table 1). However, cotransfection of the ABCC6 promoters
with a construct expressing Sp1 full-length cDNA under the
Drosophila actin promoter resulted in enhancement of
luciferase activity up to B75-fold (Table 1).
DISCUSSION
The ABCC6 gene encoding MRP6 is expressed primarily in
the liver and to a lesser extent in the kidneys (Belinsky and
Kruh, 1999; Kool et al., 1999), while very low level of
expression has been observed in a number of other tissues
(Beck et al., 2003). Immunohistochemical staining with
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Figure 6. Effects of selected cytokines on the expression of human ABCC6
promoter in HepG2 cells. (a) p-2631 construct (0.8 mg) was cotransfected
with pRSV-b-galactosidase plasmids (0.2 mg) into HepG2 cells using
FuGENE6 reagent (Roche). At 18 hours after transfection, HepG2 cells were
placed in serum-free minimal essential medium for 6 hours, after which TGF-
b ( ), TNF-a ( ), or IFN-g ( ) was added in the concentrations indicated. After
incubation for 24 hours, HepG2 cells were lysed and assayed for luciferase
and b-galactosidase activities, and the results, expressed as relative luciferase
activity, are presented as mean7SD of three independent experiments, each
performed in triplicate. The activity of p-2631 promoter without cytokines
was set arbitrarily as 100. (b) Promoter constructs p-2631, p-839, p-337,
p-175, and p-55 were transfected in HepG2 cells and the cells were then
incubated with ( ) or without ( ) of 10 ng/ml of TGF-b as described. The
results, expressed as relative luciferase activity, are presented as the
mean7SD of three independent experiments, each performed in triplicate.
The activity of p-2631 promoter without TGF-b (control) was set
arbitrarily as 100.
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Figure 7. The functional role of Sp1-binding site in TGF-b stimulation of
ABCC6 gene expression. Transfection experiments were carried out using the
WT plasmid construct p-337, as well as mutated plasmids (1m to 5m p-337)
developed by site-directed mutagenesis with mutant primers, as described in
Materials and Methods. The mutated sequences within the Sp1-binding site
and the CAGA box-like sequence are indicated in the figure. The cells were
incubated with TGF-b (10 ng/ml) as described in the legend to Figure 6. The
results are expressed as relative luciferase activity, mean7SD of three
independent experiments, each performed in triplicate. The activity of p-337
promoter without TGF-b was set arbitrarily as 100.
Table 1. Cotransfection of the ABCC6 promoter-
luciferase constructs and a human Sp1 expression
vector in Drosophila SL2 cells
Luciferase activity (U 104)
Promoter
construct Sp1 +Sp1 -Fold stimulation1
p-337 1.3570.022 100.77720.47 74.6
p-249 2.4370.044 141.22715.94 58.1
Construct p-337 or p-249 (0.4 mg) was cotransfected into SL2 cells
simultaneously either with 0.4 mg of pPAC vector alone (Sp1) or the
pPACSp1 vector (+Sp1). The ABCC6 promoter activity was measured and
expressed as luciferase units (U), mean7SD (n=3).
1Fold stimulation is calculated as the ratio of +Sp1/Sp1 for each
promoter.
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antibodies recognizing MRP6 has located it to the basolateral
plasma membrane of hepatocytes (Scheffer et al., 2002), a
feature consistent with the presence of three membrane-
spanning domains in the protein. Highly sensitive multi-
round reverse transcriptase-PCR and RNase protection assay
approaches have suggested expression also in other tissues,
including skin and vessel wall, albeit at a much lower level
(Bergen et al., 2000). Consequently, the gene potentially has
transcriptional cis-elements that confer high liver-specific
expression to this gene. In this study, we first explored liver
specificity of the ABCC6 expression by utilizing HepG2 cells,
a hepatoma cell line that has an expression profile
characteristic of hepatocytes (Khalil et al., 2001). We
developed a number of 50 deletion promoter–reporter gene
constructs and transfected them into HepG2 cells, as well as
to a number of other established cell lines of mesenchymal or
epithelial origin. Transient transfections revealed signifi-
cantly, 450-fold, higher expression of the promoter con-
structs in HepG2 cells as compared with HEK293 cells or
HT1080, a fibrosarcoma cell line. Thus, the ABCC6 promoter
apparently contains features that confer high level of
expression in the liver.
Initial scanning of the nucleotide sequence information
within 2631 bp upstream from the transcription initiation site
of the ABCC6 gene revealed the presence of two sequence
motifs with homology to the consensus CCAAT-binding site.
The corresponding enhancer-binding protein has been shown
to be a liver-enriched transcription factor presumably
participating in hepatic differentiation and involved both in
determination and maintenance of the hepatic phenotype
(Hayashi et al., 1999). Use of 50-deletion constructs in
transient transfection assays revealed, however, that elimina-
tion of these CCAAT elements (at 375 to 366 and 336
and 330) from the promoter had no appreciable effect on
the promoter activity in HepG2 cells. In contrast, elimination
of the promoter segment between 249 and 176 resulted in
significant (480%) reduction in its activity. This finding was
similar to that reported by Ara´nyi et al (2005), who noted
B50% reduction when the sequence from 332 to 145
was eliminated from their promoter construct. The sequence
between 249 and 176 was found to contain an NF-kB-like
segment (235 to 226), which differed from the NF-kB
consensus sequence by one nucleotide substitution. This
sequence was shown to bind, in a specific manner, nuclear
proteins isolated from HepG2 cells, and competition assays
suggested the importance of distinct cytosine residues within
the 30-end of this 10-bp sequence. This NF-kB-like sequence
represents a novel liver-specific element. It should be noted
that careful sequence analysis failed to identify other,
previously established sequences for liver-enriched transcrip-
tion factors, including hepatocyte nuclear factors 1, 3, and 4
(Hayashi et al., 1999). It is conceivable, therefore, that the
presence of this novel cis-element is responsible for the high
level of expression of ABCC6 in the liver.
Liver-specific expression of p-2631 construct was also
alluded to by high level of expression in vivo following its
injection to the tail vein of normal mice. The rapid injection
of the large volume of fluid enables DNA delivery to the liver
by causing a transient right-sided congestive heart failure and
backpressure to the liver vessels (Zhang et al., 1999).
Unexpectedly, the expression of the p-249 construct, which
showed somewhat higher level of expression in HepG2 cells
in culture, was significantly lower than that of p-2631. These
findings may reflect the fact that expression of genes in in
vivo may be more complex and involves a number of
additional factors (Figure 9). Nevertheless, our results
indicate that the expression of the p-2631 construct contain-
ing human ABCC6 promoter segment is high both in vitro and
in vivo. In this context, it should be noted that human ABCC6
has at least two pseudogenes, ABCC6-C1 and ABCC6-C2,
that extend from exon 1 to exon 9 and to exon 4, respectively,
and contain 50-flanking sequences. Although ABCC6-C1 is
99.995% homologous with ABCC6, there are a number of
differences in the 50-region which allow distinction between
the pseudogene and the functional WT gene (Pulkkinen et al.,
2001).
We further examined the capacity of the 2631 to þ30
promoter region to bind transcription factors using a protein/
DNA array. This recently developed technology is a
significant improvement over gel mobility-shift assays, and
1 2 3 4 5 6 7 8 9 10
SS
NS
Competitor WT Sp1 M1 M2− − − −
− −
− − − − − − − −+ +
− + − − − − − −− +
− −Fold excess 50 50 50 100 50 100
WT(−62/−45)
M1(Mut1−62/−45)
M2(Mut2−62/−45)
Sp1
Sp3
Sp3
Sp3 Ab
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a
b
Figure 8. Sp1 and Sp3 proteins bind to the proximal promoter region of the
human ABCC6 gene. (a) Sequences of WT62/45 and the corresponding
mutant (M1, M2) oligonucleotides are shown. (b) WT62/45 oligonucleo-
tide was labeled with [g-32P]dATP and used as a probe in EMSA, with nuclear
extracts prepared from HepG2 cells (all lanes). Supershift experiments (lanes
2–4) were performed by 1 hour preincubation of the reaction mixture with
2mg of each antibody prior to the addition of the radiolabeled probe.
Competition experiments (lanes 5–10) were performed with 50- or 100-fold
excess of the unlabeled WT62/45, mutated (M1, M2), or consensus Sp1-
binding oligonucleotide. Arrows on the left indicate the positions of specific
Sp1 or Sp3 DNA/protein complexes. Arrows on the right refer to supershift
(SS) or nonspecific (NS) DNA/protein complexes.
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allows functional analysis of dozens of eukaryotic transcrip-
tion factors at a time. This approach identified 18 putative
transcription factors in the sample bound to DNA, but their
counterpart cognate-binding sequences were identified only
in case of four of them, activator protein-2, USF-1, NF-kB,
and epidermal growth receptor. The functionality of NF-kB
was suggested by 50 deletion analyses as well as by mutation
analysis altering the NF-kB binding (see Results), while the
putative functions of the other three factors are currently
untested. It should be noted that computer searches for 14
transcription factors identified by the protein/DNA array
approach did not find the corresponding cognate-binding
sequences in DNA. This could be explained in some cases by
the possibility that these factors do not directly bind to DNA
but form complexes with other factors. The second explana-
tion may reside in the fact that the stringency of the search
did not allow recognition of binding sites with o80%
homology with the consensus sequence. Finally, there may
be some crosshybridization between the families of transcrip-
tion factors. For example, while binding signals for PAX-5
and hepatocyte nuclear factor-4 were noted (see Figure 5),
no consensus-binding sites for these factors were identified.
However, consensus sites for PAX-4 and hepatocyte
nuclear factor-3b were identified with partial sequence
homologies.
The complexity of the transcriptional regulation of ABCC6
has also been attested by a recent study identifying a DNA
methylation-dependent activator sequence in ABCC6 (Ara´nyi
et al., 2005). Specifically, these authors identified both
activator and repressor sequences in the proximal promoter
region. The most potent activator sequence consisted of
conserved elements protected by DNA methylation in
nonexpressing cells (Ara´nyi et al., 2005). These findings,
together with our results, raise the possibility that mutations
in the regulatory regions of the ABCC6 gene may underlie
some cases of PXE. However, besides large genomic
deletions affecting the promoter region, no regulatory
mutations have been disclosed in the ABCC6 gene (Miksch
et al., 2005; our unpublished results).
Another novel observation derived from the present study
is that cytokines, including TGF-b, TNF-a, and IFN-g, are able
to modulate the ABCC6 promoter activity. In particular, TGF-b,
a profibrotic cytokine in the liver (Bissell et al., 2001),
significantly upregulated the ABCC6 promoter activity.
Scanning of the promoter sequence for putative TGF-b
response elements identified a CAGA box-like sequence
(GACAGACAGA) overlapping the transcription initiation site
(3 to þ7). This segment has similarity to the consensus
motifs for Smad binding (GTCTAGAC, so-called Smad-
binding element, and AG(C/A)CAGACAC, so-called CAGA
box). Both sequences contain the core motive AGAC, which
represents the optimal binding sequence for Smad3 and
Smad4 (Shi et al., 1998; Zawel et al., 1998), a sequence also
present in the CAGA box-like sequence in the ABCC6
promoter. However, mutation of the CAGA box-like
sequence by 2-bp substitutions (see Figure 7) failed to abolish
the TGF-b responsiveness of the promoter. The inability of the
CAGA box-like sequence to serve as a functional TGF-b
Figure 9. Nucleotide sequence of human ABCC6 promoter region and
positions of selected cognate transcription factor-binding sites. The sequence
extending from 2631 to þ30 was scanned for transcription factor-binding
sites by using ConSite (Softberry, Inc., version 2.2004) combined with
TFSEARCH (version 1.3, Kyoto University, Japan). The putative recognition sites
for selected transcription factors, including those identified by a protein/DNA
array (see Figure 5 and text), are underlined. The translation initiation codon
(ATG) is in bold, and the transcription initiation site is referred to by þ1. The 50
ends of deletion constructs developed in this study are indicated by arrowheads.
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response element through Smad binding may relate to its
position within the gene.
In contrast to the CAGA box-like sequence, an upstream
Sp1-binding site at –58 to –49 was shown to be critical for
TGF-b response within the ABCC6 promoter. Specifically, 2-
or 4-bp substitutions within the Sp1 consensus sequence
entirely abolished the responsiveness to TGF-b. EMSA with
supershift using specific antibodies identified Sp1 and Sp3 as
nuclear proteins specifically binding to the Sp1 cognate
sequence in the ABCC6 gene promoter. Previous studies have
suggested that Sp1 binding is necessary for TGF-b1-induced
expression by a number of genes, as exemplified by proa2(I)
collagen and b5 integrin (Lai et al., 2000; Poncelet and
Schnaper, 2001), and it has been suggested that gene
activation in these cases may involve cooperation between
Smad3 and Sp1. However, Sp1-binding site has been shown
to function as a distinct TGF-b responsive element for
promoter expression and Sp1 by itself can mediate this
response (Li et al., 1998). In case of ABCC6 promoter, site-
directed mutagenesis of the Sp1 site alone was able to
abrogate the TGF-b responsiveness, suggesting a critical role
for this cis-element in regulation of the corresponding
gene expression. The expression of the ABCC6 promoter
was also shown to be dependent on Sp1 protein by the
use of Drosophila SL2 cells. This is an established in vitro
model to study the role of Sp1, since these cells are devoid
of endogenous Sp1, while all mammalian cells contain
this protein (Courey and Tjian, 1988). Specifically, transfec-
tion of two promoter–luciferase constructs (p-337 and p-249),
both of which contain the Sp1 sequence at 58 to 49, to
SL2 cells resulted in low level of expression. However,
cotransfection with a construct expressing Sp1 under the
Drosophila actin gene promoter resulted in up to 75-fold
enhancement of the ABCC6 promoter activity. These
observations clearly attest to the importance of Sp1 in
regulation of the ABCC6 promoter activity and its respon-
siveness to TGF-b.
MATERIALS AND METHODS
Cell culture
All mammalian cell lines and human dermal fibroblasts, obtained
from neonatal foreskin, were cultured in medium supplemented with
10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 IU/ml
penicillin, and 100mg/ml streptomycin (Cellgro, Mediatech, Inc.,
Herndon, VA). In case of human HepG2 hepatoma cells, the
medium was minimal essential medium (Cellgro), while human
dermal fibroblasts, HaCaT-transformed epidermal cells, HEK293
cells, HT1080 fibrosarcoma cells, and WISH amniotic cells were
cultured in Dulbecco’s modified Eagle’s medium (Cellgro). Cultures
were maintained at 371C in a humidified atmosphere of 5% CO2 and
95% air.
Drosophila SL2 cells (kindly provided by Dr James Jaynes,
Thomas Jefferson University, Philadelphia, PA) were grown at room
temperature in Drosophila Schneider cell medium (Gibco, Carlsbad,
CA) supplemented with 10% heat-inactivated fetal bovine serum.
The experiments were approved by the Institutional Review
Board, at Thomas Jefferson University, and they adhere to the
Declaration of Helsinki Principles.
Reverse transcription-PCR
Total RNA was isolated from cultured cells using TRIzol reagent, as
recommended by the manufacturer (Invitrogen, Carlsbad, CA). First-
strand cDNA synthesis was performed using 1 mg total RNA, oligo
(dT) primer (Promega, Madison, WI), and Superscript II reverse
transcriptase (Invitrogen) according to the manufacturer’s instruc-
tions. The following primers were used: 50-ATGGCCGCGCCTGCT
GAGCCCTGC-30 (sense) and 50-CCAGTCTCTGGACAGGGGTTA
GACTGC-30 (antisense) for ABCC6; 50-GGTGAAGGTCGGAGT
CAACGGA-30 (sense) and 50-AGGTCCACCACCCTGTTGCTGT-30
(antisense) for glyceraldehyde-3-phosphate dehydrogenase as an
internal control. A 50 ml PCR reaction mixture consisted of 1 PCR
buffer, 1 Q-buffer, 2.5 U Taq polymerase (Qiagen, Valencia, CA),
200mM nucleotide mix, 15 pmol each primer, and 1 ml of reaction
mixture containing first-strand cDNA. The amplification conditions
were 941C for 5 minutes, followed by 38 cycles of 941C for
45 seconds, 681C for 45 seconds, and 721C for 1 minute, and one
cycle of 721C for 10 minutes. PCR products were separated by gel
electrophoresis on 1.5% agarose gels and stained with ethidium
bromide.
50-rapid amplification of cDNA ends analysis
50-rapid amplification of cDNA ends (RACE) analysis was performed
with SMART RACE cDNA amplification kit (Clontech Laboratories,
Inc., Palo Alto, CA) using 1 mg total RNA isolated from the human
HepG2 hepatoma cells. First-strand cDNA synthesis was performed
using Superscript II reverse transcriptase (Invitrogen), SMART II oligo-
nucleotide, and 50-RACE cDNA synthesis primer, according to the
manufacturer’s instructions (Clontech Laboratories, Inc.). 50-RACE
PCR was performed using a universal primer contained in the kit,
ABCC6 gene-specific primer (MRP6-1: 50-CCAGTCTCTGGACAGG
GGTTAGACTGC-30) located in exon 5, and Advantage 2 polymer-
ase. The amplified products were diluted 50-fold, and a volume of
1ml was used in nested 50-RACE with nested universal primer and the
second ABCC6 gene-specific primer (MRP6-2: 50-GGAACACTGCG
AAGCTCATCGTGG-30) located at the exon 3–4 border, according to
the manufacturer’s instructions (Clontech Laboratories, Inc.). The
products were cloned into the pCR4-TOPO vector as recommended
by the manufacturer (Invitrogen). Recombinant plasmids were
purified with Miniprep Kit (Qiagen) and subjected to nucleotide
sequence analysis using ABI 377 DNA sequencer.
Promoter plasmid constructs
A 2661-bp fragment spanning from 2631 to þ 30 of the promoter
region of the human ABCC6 gene was prepared by PCR amplifica-
tion of the human genomic DNA using a sense primer (2631F: 50-
GTGGTACCAAGGCGTACAGCCACTGTGA-30) containing a KpnI
restriction site and an antisense primer (þ 30R: 50-TACTCGAGTTC
TGTCGTCGTGGGTCCCAGCGT-30) containing an XhoI restriction
site. The PCR products were separated by agarose gel electrophoresis
and extracted from a gel slice (Qiagen). The purified fragment was
digested with KpnI and XhoI, and cloned into pGL3 basic luciferase
vector (Promega) between KpnI and XhoI sites to generate the p-
2631 construct. Additional reporter gene constructs containing
sequentially truncated fragments from the 50-end of p-2631, span-
ning from 1729, 839, 404, 337, 249, 175, 109, and 55
to þ 30 of the ABCC6 promoter region were similarly prepared using
sense primers containing a KpnI restriction site and the antisense
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primer þ 30R. Mutagenesis of the Sp1-binding site and CAGA box-
like sequence in p-337 reporter construct, spanning from 337 to
þ 30, was performed by site-directed mutagenesis, as described by
Ho et al. (1989) using a sense primer (337F: 50-GCGGTACCTGGA
AATTGCTGGGTCCA-30), antisense primers (þ 30R-1mCAGA: 50-TA
CTCGAGTTCTGTCGTCGTGGGTCCCAGCGTCAATCTG-30, þ 30R-2m
CAGA: 50-TACTCGAGTTCTGTCGTCGTGGGTCCCAGCGTCTGAA
TG-30) containing an XhoI restriction site, and the mutant oligo-
nucleotides (mutated nucleotides are underlined in bold). The final
constructs were sequenced in both directions to ensure correct
nucleotide sequence. The sequence of the insert in p-2631 construct
confirmed its fidelity with human ABCC6 database sequence
(Figure 9). Computer analysis of the promoter region of ABCC6
was conducted to detect putative cis-acting elements using
transcription factor databases (TFSEARCH, Kyoto University, version
1.3) and ConSite (nsiteM, Softberry, Inc., version 2.2004; www.phy-
lofoot.org).
Transient transfections and luciferase assay
Plasmid constructs used for transient transfections were prepared
using a purification kit (Qiagen). HepG2, HEK293, and HT1080 cells
were plated on 35-mm dishes 24 hours prior to transfection and
grown to approximately 80% confluency. The cells were transfected
with 0.8 mg of experimental plasmid and 0.2 mg of pRSV-b-
galactosidase plasmid as an internal control of transfection
efficiency, using FuGENE 6 transfection reagent according to the
manufacturer’s instructions (Roche Diagnostic Co., Indianapolis, IN).
For Sp1 cotransfections in Schneider Drosophila SL2 cells, the same
transfection methods were used, except that 0.4 mg of the ABCC6
promoter–luciferase constructs were cotransfected with 0.4 mg of
pPACSp1 (Sp1 expression vector) or pPAC (empty vector as control),
which were a generous gift from Dr Robert Tjian, University of
California, Berkeley. In addition, in each experiment, 0.2 mg of
pHSPLacZ was used as an internal control of transfection efficiency
(Kadonaga et al., 1987).
For experiments with cytokines, HepG2 cells were washed twice
with sterile phosphate-buffered saline 18 hours after transfection and
then incubated in serum-free minimal essential medium for 6 hours
prior to addition of the cytokines for 24 hours. Incubations were
performed with human TGF-b (R&D systems, Minneapolis, MN),
human TNF-a (R&D systems), and human interferon-g (IFN-g, Roche
Diagnostic Co.).
The transfected cells were harvested in reporter lysis buffer
(Promega) and used to measure the luciferase activity with the
Luciferase Assay Reagent (Promega) using Lumat LB 9507 lumin-
ometer (Berthold, Wildbad, Germany). The b-galactosidase activity
was determined according to standard protocols (Sambrook et al.,
1989), and luciferase activity (arbitrary units) was divided by
b-galactosidase activity in the same sample (densitometric units at
420 nm) to correct for transfection efficiency and expressed as
relative luciferase activity. Luciferase assays were carried out in
triplicate, and each experiment of transfection was repeated at least
three times. Data shown in the figures represent the mean7SD of
three independent experiments.
To investigate the activity of ABCC6 promoter–luciferase reporter
gene construct in vivo, B3.5-month-old male FVB/N mice were
used for tail vein injections with the constructs. A CMV–lacZ
construct was injected as a positive control to check gene transfer
efficiency to different tissues, and Ringer’s solution was injected as a
negative control. The injections were peformed using a 27-gauge
needle and 100 mg of each DNA construct in 2 ml of Ringer’s
solution within 7 seconds. Several tissues, including the entire liver,
were collected from each injected mouse at day 2 postinjection for
luciferase assay or for b-galactosidase staining according to standard
protocols (Manthorpe et al., 1993; Zhang et al., 1999). The luciferase
activity (arbitrary units) was normalized to per mg of liver extract
protein and expressed as relative luciferase activity. Each assay was
performed in triplicate.
EMSA
Nuclear extracts were prepared from HepG2 cells according to an
established protocol (Andrews and Faller, 1991) and stored at 801C
until use. The protein concentration in the extracts was determined
by a commercial assay kit (Bio-Rad Laboratories, Hercules, CA).
Double-stranded oligonucleotides (239/222 and 62/45) were
end-labeled with [g-32P]dATP by T4 polynucleotide kinase (Prome-
ga). In all, 6mg of the nuclear extract was incubated in the binding
buffer (10 mM Hepes (pH 7.6), 4% glycerol, 1% Ficoll, 25 mM KCl,
1 mM dithiothreitol, 0.5 mM EDTA, and 25 mM NaCl) containing 1mg
poly(dI-dC) (Roche Diagnostic Co.) and 20 mg bovine serum albumin
on ice for 10 minutes. End-labeled oligonucleotides, 60,000 c.p.m.,
were added to the mixture and incubated at room temperature for
20 minutes. For competition experiments, 50- or 100-fold molar
excess of unlabeled oligonucleotides were added to the binding
reaction mixture 10 minutes prior to the addition of the labeled
probe. Oligonucleotides containing Sp1 or NF-kB consensus-
binding site were purchased from Promega. For supershift experi-
ments, 2mg of antibodies against Sp1 or Sp3 (Santa Cruz
Biotechnology, Santa Cruz, CA) were incubated with the binding
reaction mixture on ice for 1 hour before the labeled probe was
added. The DNA–protein complexes were separated by electrophor-
esis on 4% polyacrylamide gel in 0.5 TBE at 200 V for 2 hours at
41C, fixed for 30 minutes in 30% methanol and 10% acetic acid,
vacuum-dried, and autoradiographed.
Protein/DNA array
A 2661-bp fragment of ABCC6 promoter region, extending from
2631 to þ 30, was excised from p-2631 construct with restriction
enzymes KpnI and XhoI, and labeled with biotin using Bio-16-dUTP
(Roche, Mannheim, Germany) and the Klenow fragment of DNA
polymerase I (Invitrogen). Unincorporated Bio-16-dUTP was re-
moved by a spin column and the biotin-labeled DNA fragment was
coupled to the M-280 streptavidin magnetic beads (Dynal Biotech,
Oslo, Norway) under the conditions suggested by the manufacturer.
The DNA-coupled magnetic beads were incubated with 500 mg
protein in HepG2 nuclear extracts for 2 hours at 41C in the binding
buffer (4% Ficoll, 20 mM Hepes, pH 7.9, 1 mM EDTA, 1 mM
dithiothreitol, 50 mM KCl, 0.05% Triton X-100, 10% glycerol) with
an excess amount of dC-dI for competition of nonspecific binding.
After several washes, the bound proteins were dissociated from the
DNA-coupled beads by incubation in a buffer containing 2 M NaCl,
for 60 minutes on ice.
The bound proteins extracted from the 2661-bp promoter region
fragment were incubated with the TranSignal (Panomics, Redwood,
CA) probe mix, a set of 54 biotin-labeled DNA-binding oligonucleo-
tides corresponding to the consensus sequences for the correspond-
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ing transcription factors, respectively, to allow the formation of
DNA/protein complexes. The transcription factor-bound probes
were isolated and then dissociated from the DNA/protein com-
plexes, and used to hybridize to the TranSignal Array that had been
spotted with complementary consensus-binding sequences of the
transcription factor probes, at 421C for 8 hours. Hybridization
signals were visible after exposure to X-ray film following chemi-
luminescent detection. Array hybridization was repeated using the
nuclear extracts prepared separately and the same results were
obtained.
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